MaxCyte (MXCT -0.97%), a cell engineering and biotechnology platform provider, reported its second quarter 2025 results on August 6, 2025. The most important news was an 18% year-over-year decline in total revenue (GAAP) and a downward revision of its full-year outlook. Revenue (GAAP) was $8.5 million, underperforming analyst expectations by about$1.1 million (GAAP), while GAAP net losses widened compared to the prior-year period. Earnings per share (EPS) (GAAP) matched forecasts, but the company cited con ...